296
Participants
Start Date
September 15, 2022
Primary Completion Date
November 1, 2024
Study Completion Date
February 28, 2025
Reamberin
Reamberin® in the average daily dose of 10 ml/kg daily
City Clinical Hospital of Emergency Medical Care, Kaliningrad
K.N. Shevchenko Kaluga Regional Clinical Hospital of Emergency Medical Care, Kaluga
M.A. Podgorbunsky Kuzbass Clinical Hospital of Emergency Medical Care, Kuzbass
Buyanov City Clinical Hospital, Moscow
KORSAKOV Medical Center, Moscow
N.V. Sklifosovsky Research Institute of Emergency Care of the Moscow City Health Department, Moscow
Negovsky Research Institute of General Intensive Care Medicine, Moscow
Zhukovskaya City Clinical Hospital, Moscow
City Clinical Hospital No. 2, Novosibirsk
City Clinical Hospital of Emergency Medicine No. 1, Omsk
Regional Clinical Hospital,, Ryazan
City Mariinskaya Hospital, Saint Petersburg
City Narcological Hospital, Saint Petersburg
Dzhanelidze St. Petersburg Research Institute of Emergency Medicine, Saint Petersburg
State Healthcare Institution Saratov Yu. Ya. Gordeev City Clinical Hospital No. 1, Saratov
V.N. Koshelev City Clinical Hospital No. 6, Saratov
Tyumen State Medical University, Tyumen
Yaroslavl Regional Clinical Narcological Hospital, Yaroslavl
POLYSAN Scientific & Technological Pharmaceutical Company
INDUSTRY